Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9PYF

uPA Inhibitory Fab AB2 Complex

9PYF の概要
エントリーDOI10.2210/pdb9pyf/pdb
分子名称AB2 Fab Light Chain, Urokinase-type plasminogen activator, AB2 Fab Heavy Chain, ... (4 entities in total)
機能のキーワードinhibitory antibody, serine protease, urokinase plasminogen activator, site directed, protein binding
由来する生物種Homo sapiens
詳細
タンパク質・核酸の鎖数5
化学式量合計124365.82
構造登録者
Anderson, K.J.,Bohn, M.F. (登録日: 2025-08-07, 公開日: 2025-08-27)
主引用文献Sevillano, N.,Bohn, M.F.,Zimanyi, M.,Chen, Y.,Petzold, C.,Gupta, S.,Ralston, C.Y.,Craik, C.S.
Structure of an affinity-matured inhibitory recombinant fab against urokinase plasminogen activator reveals basis of potency and specificity.
Biochim Biophys Acta Proteins Proteom, 1869:140562-140562, 2021
Cited by
PubMed Abstract: Affinity maturation of U33, a recombinant Fab inhibitor of uPA, was used to improve the affinity and the inhibitory effect compared to the parental Fab. Arginine scanning of the six CDR loops of U33 was done to identify initial binding determinants since uPA prefers arginine in its primary substrate binding pocket. Two CDR loops were selected to create an engineered affinity maturation library of U33 that was diversified around ArgL91 (CDR L3) and ArgH52 (CDR H2). Biopanning of the randomized U33 library under stringent conditions resulted in eight Fabs with improved binding properties. One of the most potent inhibitors, AB2, exhibited a 13-fold decrease in IC50 when compared to U33 largely due to a decrease in its off rate. To identify contributions of interfacial residues that might undergo structural rearrangement upon interface formation we used X-ray footprinting and mass spectrometry (XFMS). Four residues showed a pronounced decrease in solvent accessibility, and their clustering suggests that AB2 targets the active site and also engages residues in an adjacent pocket unique to human uPA. The 2.9 Å resolution crystal structure of AB2-bound to uPA shows a binding mode in which the CDR L1 loop inserts into the active site cleft and acts as a determinant of inhibition. The selectivity determinant of this binding mode is unlike previously identified inhibitory Fabs against uPA related serine proteases, MTSP-1, HGFA and FXIa. CDRs H2 and L3 loops aid in interface formation and provide critical salt-bridges to remodel loops surrounding the active site of uPA providing specificity and further evidence that antibodies can be potent and selective inhibitors of proteolytic enzymes.
PubMed: 33221341
DOI: 10.1016/j.bbapap.2020.140562
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.9 Å)
構造検証レポート
Validation report summary of 9pyf
検証レポート(詳細版)ダウンロードをダウンロード

251801

件を2026-04-08に公開中

PDB statisticsPDBj update infoContact PDBjnumon